Skip to main content

Table 3 Sustained Virologic Response Rates (95% Confidence Intervals) in Patients infected with HCV Genotype 3

From: Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study

 

Genotype 3 SVR, % (95% CI)

Genotype 3a SVR, % (95% CI)

Genotype 3b SVR, % (95% CI)

All patients

All patients

LDV/SOF

DAC + SOF

SOF/VEL

All patients

LDV/SOF

DAC + SOF

SOF/VEL

Patients who complete, N

303

216

7

186

23

28

NA

27

1

 All durations

96.7 (94.0–98.2)

97.2 (94.1–98.7)

85.7 (48.7–97.4)

98.4 (95.4–99.5)

91.3 (73.2–97.6)

89.3 (72.8–96.3)

NA

88.9 (71.9–96.1)

100 (20.7–100)

 12-wk treatment

96.3 (92.8–98.1)

96.9 (92.9–98.6)

80.0 (37.6–96.4)

98.5 (94.6–99.6)

91.3 (73.2–97.6)

88.9 (67.2–96.9)

NA

88.2 (65.7–96.7)

100 (20.7–100)

 16-wk treatment

93.5 (79.3–98.2)

93.8 (71.7–98.9)

NA

93.8 (71.7–98.9)

NA

83.3 (43.6–97.0)

NA

83.3 (43.6–97.0)

NA

 24-wk treatment

100 (93.8–100)

100 (91.4–100)

100 (34.2–100)

100 (91.0–100)

NA

100 (51.0–100)

NA

100 (51.9–100)

NA

SVR in the following subgroups

 No cirrhosis

99.0 (94.8–99.8)

100 (95.1–100)

100 (34.2–100)

100 (94.6–100)

100 (61.0–100)

90.9 (62.3–98.4)

NA

90.9 (62.3–98.4)

NA

 Cirrhosis

95.5 (91.6–97.6)

95.7 (91.0–98.0)

80.0 (37.6–96.4)

97.5 (92.8–99.1)

88.2 (65.7–96.7)

88.2 (65.7–96.7)

NA

87.5 (64.0–96.5)

100 (20.7–100)

 Decompensated cirrhosis

88.4 (75.5–94.9)

86.7 (70.3–94.7)

100 (20.7–100)

91.7 (74.2–97.7)

80.0 (37.6–96.4)

100 (61.0–100)

NA

100 (61.0–100)

NA

 Treatment-naive

96.8 (92.7–98.6)

95.5 (89.8–98.0)

66.7 (20.8–93.9)

96.6 (90.6–98.8)

94.4 (74.2–99.0)

100 (84.5–100)

NA

100 (84.5–100)

NA

 Treatment-experienced

96.6 (92.3–98.5)

99.1 (94.8–99.8)

100 (51.0–100)

100 (96.2–100)

80.0 (37.6–96.4)

57.1 (25.0–84.2)

NA

50.0 (18.8–81.2)

100 (20.7–100)